CN101874114A - 通过共表达真核ⅰ型干扰素反应抑制剂从而提高来自基于细菌传递系统的转基因表达的方法 - Google Patents

通过共表达真核ⅰ型干扰素反应抑制剂从而提高来自基于细菌传递系统的转基因表达的方法 Download PDF

Info

Publication number
CN101874114A
CN101874114A CN200880116402A CN200880116402A CN101874114A CN 101874114 A CN101874114 A CN 101874114A CN 200880116402 A CN200880116402 A CN 200880116402A CN 200880116402 A CN200880116402 A CN 200880116402A CN 101874114 A CN101874114 A CN 101874114A
Authority
CN
China
Prior art keywords
acid sequence
nucleic acid
sequence encoding
genetically engineered
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880116402A
Other languages
English (en)
Chinese (zh)
Inventor
杰拉尔德·C·萨多夫
穆罕默德·法可鲁丁-贾米鲁丁
拉维·P·阿南达
小约翰·F·富尔克松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeras Global TB Vaccine Foundation
Original Assignee
Aeras Global TB Vaccine Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeras Global TB Vaccine Foundation filed Critical Aeras Global TB Vaccine Foundation
Publication of CN101874114A publication Critical patent/CN101874114A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200880116402A 2007-09-12 2008-09-11 通过共表达真核ⅰ型干扰素反应抑制剂从而提高来自基于细菌传递系统的转基因表达的方法 Pending CN101874114A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/854,027 2007-09-12
US11/854,027 US7608256B2 (en) 2007-09-12 2007-09-12 Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response
PCT/US2008/075972 WO2009036137A1 (en) 2007-09-12 2008-09-11 Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type i interferon response

Publications (1)

Publication Number Publication Date
CN101874114A true CN101874114A (zh) 2010-10-27

Family

ID=40432101

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880116402A Pending CN101874114A (zh) 2007-09-12 2008-09-11 通过共表达真核ⅰ型干扰素反应抑制剂从而提高来自基于细菌传递系统的转基因表达的方法

Country Status (6)

Country Link
US (4) US7608256B2 (enExample)
EP (1) EP2188377A4 (enExample)
JP (1) JP5665541B2 (enExample)
KR (1) KR20100075884A (enExample)
CN (1) CN101874114A (enExample)
WO (1) WO2009036137A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079936A1 (zh) * 2015-11-12 2017-05-18 昕颖生医技术股份有限公司 表现异源基因的系统及其用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608256B2 (en) 2007-09-12 2009-10-27 Aeras Global Tb Vaccine Foundation Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response
WO2010025016A2 (en) * 2008-08-06 2010-03-04 Aeras Global Tb Vaccine Foundation Enhancement of transgene expression from virus-based vaccine vectors using suppressors of the type 1 interferon response
EP2421563B1 (en) 2009-04-22 2017-04-12 Massachusetts Institute of Technology Innate immune suppression enables repeated delivery of long rna molecules
US9045729B2 (en) 2009-12-10 2015-06-02 Ottawa Hospital Research Institute Oncolytic rhabdovirus
JP5886757B2 (ja) * 2010-01-04 2016-03-16 カッパーアールエヌエー，インコーポレイテッド インターフェロン調節因子８（ｉｒｆ８）に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子８（ｉｒｆ８）関連疾患の治療
WO2014127478A1 (en) 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
WO2014198002A1 (en) * 2013-06-14 2014-12-18 Ottawa Hospital Research Institute A bacterium producing an interferon binding protein and uses thereof
KR101550217B1 (ko) * 2014-03-26 2015-09-04 전남대학교산학협력단 숙주세포의 생체 회로 간섭 없이 외래 유전자를 발현하기 위한 재조합 벡터 및 이의 용도
CN108159410A (zh) * 2018-01-15 2018-06-15 重庆市卓诺科技发展有限公司 登革热病毒疫苗
GB201908729D0 (en) 2019-06-18 2019-07-31 Imp College Innovations Ltd RNA construct

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7016A (en) * 1850-01-15 Mill for grinding
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
CA2308017A1 (en) * 1997-10-30 1999-05-14 Erik S. Falck-Pedersen A method of inhibiting an immune response to a recombinant vector
US7033781B1 (en) * 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
JP5215865B2 (ja) * 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
US7608256B2 (en) * 2007-09-12 2009-10-27 Aeras Global Tb Vaccine Foundation Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079936A1 (zh) * 2015-11-12 2017-05-18 昕颖生医技术股份有限公司 表现异源基因的系统及其用途

Also Published As

Publication number Publication date
US7608256B2 (en) 2009-10-27
US20130224242A1 (en) 2013-08-29
JP5665541B2 (ja) 2015-02-04
US8414884B2 (en) 2013-04-09
US8658136B2 (en) 2014-02-25
US7883696B2 (en) 2011-02-08
US20110086066A1 (en) 2011-04-14
US20090068222A1 (en) 2009-03-12
EP2188377A1 (en) 2010-05-26
US20100003219A1 (en) 2010-01-07
KR20100075884A (ko) 2010-07-05
JP2010538649A (ja) 2010-12-16
WO2009036137A1 (en) 2009-03-19
EP2188377A4 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
US8414884B2 (en) Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response
JP2010508861A (ja) 抗原およびタンパク質毒素をコードする異種ヌクレオチド配列からなる担体としての微生物、その生成方法、ならびにその使用
EP0827410B1 (en) Method for introducing and expressing genes in animal cells
JP2003512077A (ja) アルファウイルスレプリコンを発現する侵襲性細菌
US7829104B2 (en) Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
JP5713523B2 (ja) エンドソームエスケープ能力増強組み換えｂｃｇ株類
EP2278994A2 (en) Flagellin polypeptide vaccines
Daudel et al. Use of attenuated bacteria as delivery vectors for DNA vaccines
Begnini et al. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer
Brockstedt et al. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies
Xu et al. Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella
CN102089423A (zh) 通过表达ⅰ型干扰素反应的抑制剂来增强来自基于病毒的疫苗载体的转基因表达
Becker et al. Genetic immunization: bacteria as DNA vaccine delivery vehicles
CN101076356B (zh) 分枝杆菌的电穿孔及在分枝杆菌中过表达抗原
Wiedig et al. Induction of CD8+ T cell responses by Yersinia vaccine carrier strains
JP2008521434A (ja) 組換え二重鎖ＲＮＡヌクレオカプシド類（ｒｄｓＲＮｓ）の生成および産生に有用なバクテリア・パッケージング株およびそれらの利用
JP2024542173A (ja) マクロファージを処置に適している表現型に変換するための免疫刺激細菌および処置のための対象の同定のためのコンパニオン診断法
US20080107683A1 (en) Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof
Boyle et al. Vectors for recombinant vaccine delivery
US10226521B2 (en) Genetically modified Yersinia as vaccines against Yersinia species
WO2010025016A2 (en) Enhancement of transgene expression from virus-based vaccine vectors using suppressors of the type 1 interferon response
KR20100128098A (ko) 돼지 인터류킨-18 유전자를 발현하는 살모넬라 균주 및 이를 함유하는 경구 투여용 조성물
Vishanath DEEMED UNIVERSITY
Endmann Novel Salmonella vectors with in vivo amplifiable plasmids for vaccination and tumor therapy
Nagata et al. 15 Anti-Infective Vaccine Strategies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101027